Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tracon Pharmaceuticals has treated the first cancer patient in a Phase I clinical trial with oral TRC102, a novel anticancer drug intended to reverse resistance to Alimta chemotherapy by targeting a specific DNA repair pathway.
Subscribe to our email newsletter
The Phase I trial is designed to assess the safety, tolerability and pharmacokinetics, as well as preliminary antitumor activity of TRC102 in patients with advanced cancer who also receive Alimta.
Intravenous TRC102 is also being dosed to cancer patients in a Phase I clinical trial in combination with Temodar being conducted at University Hospitals Case Medical Center.
TRC102 is a small molecule that has been shown to reverse resistance to the chemotherapy agent Alimta in models of human cancer, by targeting the base excision repair pathway used to repair chemotherapy-induced DNA damage.